Astellas announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to isavuconazole for the treatment of invasive candidiasis. Isavuconazole is a once-daily intravenous ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Astellas announced safety and efficacy results from its Phase 3 SECURE trial with isavuconazole for the treatment of invasive asperigillosis. Isavuconazole is an investigational once-daily intravenous ...

Isavuconazole is being jointly developed by Astellas and Basilea Pharmaceutica Ltd. Currently, isavuconazole is in the phase III ACTIVE study, which is the third study in a phase III program on the ...

Mumbai: BDR Pharmaceutical announced the launch of the first-of-its-kind generic drug, Zisavel Capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of ...

The antifungal drug isavuconazole is as effective as voriconazole for the treatment of invasive mold disease and causes significantly fewer drug-related adverse events, according to the results of a ...

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA® (isavuconazonium ...

Four years after Astellas Pharma entered a multimillion-dollar license, co-development, and co-promotion agreement with Basilea Pharmaceutica for Basilea’s azole antifungal agent isavuconazole, ...

New Delhi, Apr 25 (PTI) Gufic Biosciences on Monday said it has received an approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market a drug used to treat ...

Please provide your email address to receive an email when new articles are posted on . Isavuconazole treatment showed similar efficacy to amphotericin B against mucormycosis, according to data ...